Related Experiment Video
Updated: Jun 30, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
The p53-mediated cell cycle regulation is a potential mechanism for emodin-suppressing osteosarcoma cells
Qian Zhang1, Shuli Hao2, Guangyou Wei3
1Department of Pharmacy, Bozhou People's Hospital, Bozhou, 236800, Anhui Province, China.
Background:
As the most common primary bone cancer, the therapy of osteosarcoma requires further study. An anthraquinone derivative, emodin, has been found to have anticancer potential. We proposed that emodin suppresses osteosarcoma by cell cycle regulation mediated by p53.
Methods:
This study determined the effect of emodin on viability and apoptosis of 6 osteosarcoma cell lines (p53 null cells MG63, G292, and A-673; p53 mutated cells HOS and SK-PN-DW; p53 expressing cells U2OS and 2 osteoblast cell lines), then knockdown p53 in U2OS, and observed the impacts of emodin on p53, p21, cyclin proteins, and cell cycle.
Results:
High dose emodin (40-160 μM) induced cell death and apoptosis of all the cell lines; medium dose emodin (20 μM) preferentially inhibited osteosarcoma cells; low dose emodin (1-10 μM) preferentially inhibited p53 expressing osteosarcoma cells. Emodin dose-dependently inhibited p53 and p21 in U2OS. Emodin at 10 μM decreased the expression of Cdk2, E2F, and Cdk1; and increased RB but had no effects on cyclin E and cyclin B. The knockdown of p53 almost eliminated all the impacts of 10 μM emodin on cell cycle proteins.
Conclusions:
Emodin suppresses U2OS by p53-mediated cell cycle regulation.
Insights
Emodin, a natural compound, effectively suppresses osteosarcoma cell growth by regulating the cell cycle through the p53 pathway. This study highlights emodin
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osteosarcoma, the most common primary bone cancer, necessitates novel therapeutic strategies.
- Emodin, an anthraquinone derivative, exhibits potential anticancer properties.
- The proposed mechanism involves emodin-induced suppression of osteosarcoma via p53-mediated cell cycle regulation.
Purpose of the Study:
- To investigate the effects of emodin on osteosarcoma cell viability and apoptosis.
- To elucidate the role of p53 in emodin's mechanism of action.
- To determine the impact of emodin on key cell cycle regulatory proteins.
Main Methods:
- Assessed emodin's impact on viability and apoptosis across six osteosarcoma cell lines with varying p53 statuses.
- Utilized p53 knockdown in U2OS cells to investigate the p53-dependent effects of emodin.
- Quantified changes in p53, p21, cyclin proteins, and cell cycle progression following emodin treatment.
Main Results:
- Emodin induced cell death and apoptosis in a dose-dependent manner across all tested osteosarcoma cell lines.
- Low-dose emodin (1-10 μM) preferentially inhibited osteosarcoma cells expressing p53.
- Emodin treatment modulated p53, p21, Cdk2, E2F, Cdk1, and RB expression, impacting cell cycle progression, with p53 knockdown abrogating these effects.
Conclusions:
- Emodin effectively suppresses osteosarcoma cell growth.
- The anticancer effects of emodin are mediated through p53-dependent cell cycle regulation.
- Emodin represents a potential therapeutic agent for osteosarcoma.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...
Inhibition of Cdk Activity
Mitogens and the Cell Cycle

